Medical network - February 20 since 2011, released in 2012 as "the most severe in the history of resistance to limit the clinical application of antibacterial drugs management method" after discussion and the formal draft, clinical use of antibacterial drugs in our country in resistance to limit the new normal.
After years of annual national or local policies, notification, released in 2015, the clinical application of antibacterial drugs guidelines (2015 edition) ", or even who planning commission in 2016, the CFDA 14 ministries jointly issued "containing bacteria resistant national action plan (2016-2020)", the resistance to limit should be brought into the national strategic planning. However, some antibiotic was the support of national policy.
▍ "" much starker choices-and graver consequences-in" national tuberculosis control program"
Promulgated by the state council on February 16, "" much starker choices-and graver consequences-in" national tuberculosis control program ", points out that at present our country still is one of 30 high TB burden countries around the world, each year about 900000 new TB cases patients, the third in the world. Prevention and control of many kinds of ways of comprehensive prevention and control measures, improve the service system, especially in childhood tuberculosis prevention and control measures should be improved. Expected by 2020, tuberculosis morbidity and further reduce the death toll, the incidence of TB down to about 58/10 of all the following, the incidence of tuberculosis epidemic on the high side area down 20% compared with 2015.
The programme is particularly need to medical people attention is specifically to strengthen security anti-tb drug supply, perfect the mechanism of drug purchase, based on the characteristics and the market competition situation, drug classification procurement, to ensure that procurement, reasonable price, supply adequate drug quality and safety.
Encourage the provinces (autonomous regions and municipalities) drug procurement agencies to anti-tb drugs joint procurement. Clinical dosage for clinical required, low market prices, centralize and hanging nets, small anti-tb drugs by the hospital and enterprise bargaining purchase, guarantee treatment requirements.
▍ antimicrobials in tuberculosis clinical pathway middle and high frequency
On December 8, 2016, the national health and family planning commission general office issued about clinical path implementation related diseases, by the Chinese medical association published 1010 kinds of clinical path, the author found that, by retrieving diseases associated with tuberculosis (TB) clinical pathway have eight, mainly for tuberculosis related diseases. One specific mention treatment of TB disease related path has six, involving major therapeutic drug varieties have 22.
Points in the disease, a single TB related diseases involving the most drugs up to 20, the details are as follows:
Note: according to the medicine institute published clinical pathway
The 22 drugs has ethambutol, pyrazinamide and rifampicin, isoniazid four drugs in clinical pathway high frequency, in 4-5 TB related diseases in clinical pathway.
▍ antimicrobials by policy support
From drugs belonging to drugs for the treatment of tuberculosis clinical pathway involved in classification of view, these drugs in addition to the prednisone, other drugs as part of the antibacterial drugs. Details are as follows:
"" much starker choices-and graver consequences-in national tuberculosis control program", "clearly put forward to ensure TB treatment related to the supply of drugs, and those drugs are mentioned in the clinical pathway of medicines, these antibacterial drugs production and sales of all visible by relevant policy support and encouragement, not affected by the resistance limit. Accordingly, these drugs related to production and sales of manufacturers will benefit.
|
